A delayed puberty hormone panel measures signals from the pituitary gland and sex hormones from the ovaries or testes to help explain why puberty has not started or is progressing slowly. The core tests are usually luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol in girls, and testosterone in boys. Results are interpreted with age, growth pattern, bone age, examination, chronic health conditions, nutrition, exercise, and family history. High LH and FSH with low sex hormones suggest primary ovarian or testicular failure. Low or prepubertal LH and FSH with low sex hormones may reflect constitutional delay, chronic illness, low energy availability, or hypothalamic-pituitary disease. A single basal sample can be inconclusive because early puberty hormones are released in nighttime pulses. Delayed puberty is commonly defined as no breast development by age 13 in girls or no testicular enlargement by age 14 in boys, although individualized assessment matters.
- Delayed puberty usually means no breast development by 13 or no testicular enlargement by 14.
- High LH and FSH with low estradiol or testosterone suggest primary gonadal failure.
- Low or normal LH and FSH with low sex hormones can reflect constitutional delay or central suppression.
- Growth chart, bone age, examination, and chronic illness history are as important as the blood panel.
- Early puberty hormone secretion is pulsatile, so one normal or low LH result may not settle the diagnosis.
- Severe headache, visual change, excessive thirst, neurologic symptoms, or sudden growth failure needs prompt evaluation.
Table of Contents
- What the Delayed Puberty Hormone Panel Measures
- Why the Test Is Ordered
- Preparation, Timing, and the Testing Process
- Normal Range and How Results Are Interpreted
- Patterns With High LH or FSH
- Patterns With Low Puberty Hormones
- How Results Fit With Other Hormones and Tests
- Next Steps After the Result
What the Delayed Puberty Hormone Panel Measures
Puberty begins when the hypothalamus releases GnRH in pulses. GnRH stimulates the pituitary to release LH and FSH. In girls, these signals support ovarian estradiol production and follicle development; in boys, LH stimulates testicular testosterone and FSH supports Sertoli cells and sperm-producing tissue.
The panel evaluates the hypothalamic-pituitary-gonadal axis at several levels. LH and FSH show pituitary signaling, while estradiol or testosterone reflects gonadal output. Additional tests identify thyroid, prolactin, adrenal, genetic, or systemic causes.
A hormone result is a measurement made under defined laboratory conditions, not a diagnosis by itself. The same concentration can carry different meaning at different ages, cycle stages, pregnancy stages, or times of day. Laboratories also use different analyzers, calibration systems, antibodies, and calculation methods. For that reason, the reference interval printed beside the result should take priority over a range copied from another report or website.
Constitutional delay of growth and puberty is common, especially in boys, and often follows a family pattern of late maturation. It is a diagnosis made after reviewing growth and excluding disease, not a conclusion drawn from one low hormone result.
When basal results remain unclear, a GnRH stimulation test may be used in selected specialist evaluations.
Why the Test Is Ordered
Testing is appropriate when physical development is absent beyond the usual age, puberty begins and then stalls, or growth and symptoms suggest an endocrine or systemic disorder.
- No breast development by about age 13 or no first period by age 15.
- No testicular enlargement to at least 4 mL by about age 14.
- More than four to five years between the first signs of puberty and completion.
- Puberty that starts but stops progressing.
- Short stature, falling growth velocity, undernutrition, excessive training, or chronic illness.
- Loss of smell, headaches, visual symptoms, genital differences, or a family history of gonadal failure.
Clinicians first confirm the developmental stage on examination. Pubic hair alone does not prove central puberty because adrenal androgens can cause hair and body odor without activating the ovaries or testes. Growth records often reveal whether delay is longstanding or newly acquired.
Interpretation starts with the reason the test was ordered. A clinician looking for an adrenal enzyme disorder uses different cutoffs and follow-up tests than a clinician evaluating irregular periods, infertility, menopausal symptoms, or androgen deficiency. The result should be read with symptoms, examination findings, age, reproductive stage, and related laboratory values rather than compared with one universal “optimal” number.
A thyroid function panel is often included because thyroid disease can slow growth and pubertal progression.
Preparation, Timing, and the Testing Process
Morning sampling improves testosterone interpretation in boys and may better capture early pubertal signaling. The child should be clinically stable when possible.
- Bring complete growth records, puberty milestones, family timing, and the current height and weight history.
- List glucocorticoids, stimulants, antipsychotics, chemotherapy, gender-affirming hormones, and supplements.
- Report chronic bowel, kidney, lung, inflammatory, neurologic, or eating disorders.
- Schedule morning blood collection, especially when testosterone is measured.
- Follow instructions for any stimulation test or imaging arranged by pediatric endocrinology.
Basal LH measured with a sensitive assay can show pubertal activation, but low values overlap between early puberty and prepubertal states. A GnRH or GnRH-agonist stimulation test may clarify selected cases. Bone age, usually from a hand and wrist radiograph, estimates skeletal maturation and remaining growth potential.
Before collection, provide a complete list of prescription medicines, over-the-counter products, supplements, contraceptives, fertility drugs, and hormone therapy. Do not stop prescribed treatment without instructions. Some products change hormone production, while others alter binding proteins or interfere with an immunoassay. High-dose biotin is a well-known source of interference in several hormone tests, although the direction and size of the error depend on the platform.
Acute illness can temporarily suppress or stimulate reproductive signaling. A test drawn during fever, major surgery, severe calorie restriction, or intense training may describe that temporary state rather than the person’s usual hormone function. When the clinical situation is stable and there is no urgent reason to test immediately, postponing or repeating the measurement can prevent an incorrect label.
Normal Range and How Results Are Interpreted
Pediatric hormone ranges must be matched to sex, age, Tanner stage, assay, and time of day. Adult ranges are inappropriate for a child or early adolescent.
| LH/FSH | Estradiol or testosterone | Common interpretation |
|---|---|---|
| High | Low | Primary ovarian or testicular failure |
| Low or prepubertal | Low | Constitutional delay, functional suppression, or central hypogonadism |
| Pubertal | Rising | Puberty may have begun; assess pace and examination |
| Mixed or discordant | Variable | Repeat testing, assay review, or targeted evaluation needed |
| Suppressed on treatment | Treatment-dependent | Interpret against prescribed therapy and clinical goals |
Estradiol is difficult to measure accurately at very low pediatric concentrations, and testosterone requires a sensitive method. Results near a cutoff should be repeated or interpreted by a pediatric endocrinologist rather than compared with an adult internet chart.
A value close to a cutoff deserves more caution than a value that is clearly and repeatedly abnormal. Borderline results may move across the reference limit because of normal biologic variation, recent illness, sleep disruption, exercise, stress, or sample timing. Clinicians often repeat a test under better-controlled conditions before ordering imaging or beginning treatment. The repeat is most useful when the timing, medication list, and assay method are documented.
Trends can be useful when the same question is followed over time, but only when the measurements are reasonably comparable. A change between laboratories may reflect a method difference. A change after starting or stopping hormones may be expected. Record the laboratory, units, collection time, cycle day or pregnancy week, and relevant treatment so later results can be compared in context.
FSH interpretation is explained further in the FSH test guide, but pediatric reference ranges remain essential.
Patterns With High LH or FSH
High LH and FSH show that the pituitary is trying to stimulate ovaries or testes that are not producing the expected sex hormones. This is called hypergonadotropic hypogonadism.
- Turner syndrome or another cause of ovarian dysgenesis.
- Klinefelter syndrome or primary testicular dysfunction.
- Damage from chemotherapy, radiation, torsion, surgery, infection, or autoimmune disease.
- Genetic disorders of gonadal development or steroid production.
- Primary ovarian insufficiency or anorchia.
- Laboratory interpretation using an incorrect age or puberty interval.
The pattern often prompts chromosome analysis or other genetic testing, pelvic or testicular imaging, and assessment of associated health conditions. In girls, a uterus may be visible even when ovarian function is limited. In boys, inhibin B or AMH can add information about Sertoli-cell function in selected cases.
Hormone replacement is usually introduced gradually to mimic normal puberty and support bone, uterine, muscle, and psychosocial development. Fertility potential depends on the cause and should be discussed separately from the need for sex-steroid replacement.
Early specialist referral helps coordinate genetic counseling, induction of puberty, bone-health monitoring, and long-term reproductive care. Treatment should not be delayed solely to repeat clearly abnormal gonadotropins.
Girls with ovarian failure may need a focused primary ovarian insufficiency evaluation adapted for age.
Patterns With Low Puberty Hormones
Low sex hormones with low or inappropriately normal LH and FSH can reflect a normal late-maturing pattern or reduced GnRH/pituitary signaling. The clinical context separates these possibilities.
- Constitutional delay of growth and puberty.
- Low energy availability, an eating disorder, or intensive exercise.
- Chronic systemic illness or inflammatory disease.
- Congenital GnRH deficiency, sometimes associated with reduced sense of smell.
- Pituitary or hypothalamic tumor, injury, radiation, or structural difference.
- High prolactin, severe hypothyroidism, or medication effects.
Constitutional delay often includes short stature for age, delayed bone age, normal childhood growth velocity, and a family history of late puberty. Functional hypogonadism can improve when nutrition, chronic disease, or training load improves. Persistent central hypogonadism may require MRI and evaluation of other pituitary hormones.
An isolated low random LH does not prove central disease. Early pubertal secretion is strongest during sleep and occurs in pulses. Sensitive basal assays, repeat morning tests, stimulation testing, and the physical trajectory over six to twelve months may provide a clearer answer.
Treatment depends on the cause and the adolescent’s distress, bone health, and growth. A short course of low-dose sex steroid may “jump-start” puberty in constitutional delay, while permanent hypogonadism needs a planned induction and maintenance regimen.
High prolactin can suppress GnRH, so a prolactin test is often included when central suppression is possible.
How Results Fit With Other Hormones and Tests
The panel is interpreted with growth, bone age, and related endocrine tests rather than as four independent numbers.
| Clinical pattern | Laboratory pattern | Likely direction |
|---|---|---|
| Short, delayed bone age, family late puberty | Low prepubertal LH/FSH and sex hormones | Constitutional delay remains likely |
| Poor weight gain or heavy training | Low LH/FSH and sex hormones | Functional hypothalamic suppression |
| No puberty with high gonadotropins | Low estradiol/testosterone | Primary gonadal failure |
| Headache, visual change, other pituitary deficits | Low or normal gonadotropins | Central structural disease must be excluded |
| Puberty began then stopped | Falling or static sex hormones | Acquired illness, nutrition, or central cause |
TSH and free T4, prolactin, complete blood count, inflammatory markers, metabolic panel, celiac screening, and IGF-1 may be selected from the history. Tests should target plausible causes rather than create a broad untimed panel with incidental abnormalities.
Next Steps After the Result
A complete plan defines whether puberty is simply late, functionally suppressed, or permanently impaired and protects growth and bone health while the diagnosis is clarified.
- Confirm Tanner stage and plot height, weight, and growth velocity over time.
- Obtain morning LH, FSH, and sex hormones with pediatric-sensitive assays.
- Assess bone age and screen for chronic, nutritional, thyroid, and prolactin-related causes.
- Use genetic testing, pelvic or testicular imaging, MRI, or stimulation testing when the pattern indicates.
- Refer to pediatric endocrinology for absent or stalled puberty.
- Discuss treatment timing, expected changes, fertility implications, and psychosocial support.
Puberty induction is individualized. Estrogen in girls and testosterone in boys are generally started at low doses and increased over time to resemble physiologic development. The clinician monitors growth, bone age, secondary sexual characteristics, mood, blood pressure, and laboratory response.
Mental health and peer concerns deserve direct attention. Delayed puberty can cause teasing, withdrawal, or distress even when the cause is constitutional. Clear expectations and a time-based follow-up plan can reduce uncertainty.
Bring the actual report to the follow-up visit rather than only recalling that the level was “high” or “low.” The report shows units, the laboratory interval, specimen type, and sometimes the assay method. Ask whether the result needs confirmation, whether a related hormone should be measured at the same time, and what finding would change management.
A useful plan defines the next step and its timing. That may be no action, a repeat test, a dynamic stimulation or suppression test, ultrasound, semen analysis, genetic testing, or referral to endocrinology, reproductive endocrinology, urology, or maternal-fetal medicine. It should also identify symptoms that warrant earlier contact instead of waiting for the routine appointment.
Rapidly progressive symptoms deserve faster evaluation than a mild, stable laboratory abnormality. Examples include sudden virilization, severe headache with visual change, signs of adrenal crisis, heavy bleeding with dizziness, or concerning pregnancy symptoms. The laboratory number may guide the workup, but urgent decisions are driven by the whole clinical picture.
Treatment should address the confirmed cause and the person’s goals. Lowering or raising a laboratory value without establishing why it is abnormal can hide an important condition or create new problems. Hormone therapy can affect fertility, blood counts, liver function, clot risk, bone health, and pregnancy, so monitoring plans should be individualized.
Prompt evaluation is needed for severe or new headache, visual change, vomiting, excessive thirst or urination, seizures, neurologic change, or abrupt growth failure. These findings may indicate a pituitary or brain disorder requiring urgent assessment.
When a repeat measurement is planned, try to reproduce the conditions that matter for this test. Use the same laboratory when practical, note the collection time, and record any change in medicines or reproductive stage. Consistency does not remove all biologic variation, but it makes a true trend easier to distinguish from noise.
Reference intervals describe a population selected by the laboratory; they do not define a treatment target for every person. A result inside the interval can still require attention when symptoms are strong or when another hormone shows a clear mismatch. Conversely, a small deviation may not represent disease when the timing or clinical setting explains it.
A laboratory result can answer only the question built into the test. It may show hormone concentration, but it cannot by itself prove ovulation quality, egg quality, sperm production, placental health, or the cause of a symptom. Those conclusions usually require a combination of history, examination, imaging, and other targeted tests.
When fertility is the concern, age, duration of trying to conceive, menstrual pattern, pregnancy history, semen findings, and tubal or uterine factors often affect the plan as much as a single hormone value. Testing both partners in parallel can prevent months of delay and reduce the chance that an incidental hormone result distracts from a more direct cause.
When symptoms are being monitored rather than fertility, define the outcome that treatment is meant to improve. Examples include restoration of periods, relief of hot flashes, reduction of unwanted hair growth, recovery of sexual function, preservation of bone health, or safe progression of puberty. Laboratory monitoring is most useful when tied to one of these clinical outcomes.
People using nonprescription “hormone balance” products should mention them before testing. DHEA, progesterone creams, testosterone boosters, compounded preparations, and biotin can alter physiology or make results harder to interpret. Product labels may not reliably predict the dose absorbed, so the safest approach is to review the exact container or ingredient list with the clinician.
Results can also differ because laboratories report conventional and SI units. A value expressed in ng/dL cannot be compared directly with one expressed in nmol/L without a hormone-specific conversion. Always compare the number, unit, and interval together. This simple check prevents many apparent contradictions between reports.
An abnormal result can have emotional weight, especially during fertility treatment, pregnancy, or puberty evaluation. Ask the clinician to separate what is known from what remains uncertain. A clear explanation of the likely causes, the confirmation plan, and the time frame for action is more useful than trying to interpret every decimal place independently.
Clinicians also consider whether the test result agrees with the physical findings. A marked biochemical abnormality without expected symptoms may prompt confirmation with a more specific laboratory method. Strong symptoms with a normal result may lead to testing at a different time, measuring a related hormone, or looking for a nonhormonal cause.
The pace of change can be as important as the level itself. Slow changes over years commonly fit physiologic aging or a chronic endocrine condition. Changes over weeks or a few months raise more concern for a new medicine effect, pregnancy-related change, acute illness, or a hormone-producing lesion, especially when symptoms progress quickly.
No single follow-up pathway fits every abnormal value. Mild and explainable results may only need observation. Persistent or substantial abnormalities may require specialist review and tests chosen to locate the source of hormone production or the level of signaling failure. The sequence should be deliberate so that each test answers a specific unresolved question.
Keep a copy of the laboratory report and the order indication. The clinician needs more than the highlighted flag: the numeric value, unit, reference interval, specimen type, collection date and time, and any comment about the assay can change interpretation. A result copied into a patient portal message without those details may be impossible to compare with a later test. This documentation is especially important when care moves between a primary clinician, endocrinologist, fertility clinic, and hospital laboratory.
Before repeating testing, decide what the repeat is meant to resolve. It may confirm persistence, correct a timing error, remove a medication effect, or use a more specific assay. Repeating the same poorly timed test without changing the conditions often reproduces uncertainty rather than solving it. The clinician should also state what result would lead to observation, another laboratory test, imaging, or treatment.
Small deviations from a reference interval are common because the interval usually contains about 95% of a selected comparison population. Some healthy people fall outside it, while some people with disease fall inside it. The clinical importance depends on how far the value is from the limit, whether it persists, whether related hormones agree, and whether symptoms fit the physiology. A reference flag is therefore a prompt for interpretation, not proof of disease.
Hormone results are also affected by changes in binding proteins and metabolism. Liver disease, thyroid disease, kidney disease, pregnancy, body composition, and oral estrogen exposure can change measured concentrations without producing the same change in tissue effect. When a binding issue is suspected, the clinician may use a free or calculated hormone, a related binding protein, or a more specific laboratory method rather than interpreting the total concentration alone.
Fertility decisions should not be reduced to a single endocrine value. A hormone may help choose medication dose, confirm ovulation, or identify a treatable disorder, but it does not measure every step required for pregnancy. Reproductive age, sperm exposure or semen quality, tubal patency, uterine anatomy, timing, prior pregnancies, and the duration of trying all influence the next step. A balanced evaluation prevents overreaction to an incidental result.
References
- A Current Perspective on Delayed Puberty and Its Management 2024 (Review)
- Delayed Puberty Including Constitutional Delay: Differential and Outcome 2024 (Review)
- Functional hypogonadism in adolescence 2023 (Review)
- Normal and Abnormal Puberty 2024 (Review)
- Current evaluation of amenorrhea: a committee opinion 2024 (Committee Opinion)
Disclaimer
This article provides general information and cannot diagnose delayed puberty in a child or adolescent. Pediatric hormone values require age-, sex-, stage-, and method-specific interpretation. Absent or stalled puberty should be assessed by a pediatric clinician or endocrinologist.
